Company / Accounts Receivable
Syndax Pharmaceuticals Inc Accounts Receivable History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$38.0M
FY2025
5-year range
$0 / $38.0M
FY2023-FY2025
Trend
+399.8%
vs FY2024
Sector context
#75 of 113
Health Care
What the data says
At $38M, Syndax Pharmaceuticals Inc's accounts receivable ranks #75 of 113 in the Health Care sector. Improved from $0 to $38M over the past 2 years.
Based on SEC 10-K filings.
$38M in FY2025.
Improved from $0 to $38M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#75 of 113 in Health CareTop 66% of 113This company $38.0M Sector average $1.1B
▼
-96.7% below sector average
Key checks
Key Insights
- In FY2025, accounts receivable increased 399.8% year-over-year.
- Ranks #75 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $38.0M | +399.8% |
| FY2024 | $7.6M | - |
| FY2023 | $0 | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026